In osteoarthritis management, which treatment is considered for severe disease but is not first-line?

In osteoarthritis management, which treatment is considered for severe disease but is not first-line?

• A. Disease-modifying antirheumatic drugs
• B. Acetaminophen
• C. Intraarticular corticosteroids
• D. Glucosamine and chondroitin

Answer: (D)

In osteoarthritis, treatment choices ramp up as symptoms worsen, but starting points are nonpharmacologic measures plus a simple analgesic like acetaminophen. Glucosamine and chondroitin are dietary supplements that some patients try when OA is more severe, hoping for pain relief. However, large, well-designed studies have shown inconsistent or minimal benefits for pain and function, with no clear disease-modifying effect. Because of this uncertain efficacy, they aren’t considered first-line therapy, even in more advanced disease, and they don’t replace proven treatments such as acetaminophen, NSAIDs when appropriate, or short-term intraarticular corticosteroid injections for flares. They may be discussed as an adjunct for patients who want to pursue non-prescription options, but they are not the standard or primary approach for severe OA.

In osteoarthritis, treatment choices ramp up as symptoms worsen, but starting points are nonpharmacologic measures plus a simple analgesic like acetaminophen. Glucosamine and chondroitin are dietary supplements that some patients try when OA is more severe, hoping for pain relief. However, large, well-designed studies have shown inconsistent or minimal benefits for pain and function, with no clear disease-modifying effect. Because of this uncertain efficacy, they aren’t considered first-line therapy, even in more advanced disease, and they don’t replace proven treatments such as acetaminophen, NSAIDs when appropriate, or short-term intraarticular corticosteroid injections for flares. They may be discussed as an adjunct for patients who want to pursue non-prescription options, but they are not the standard or primary approach for severe OA.